Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Tamler

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Telemedicine and Telecare|October 30, 2023
Healthcare utilization impacts of an eConsult program for headache at an academic medical centerMargaret H Downes, Rachelle Morgenstern, Georges Naasan, et al.
Cardiovascular Drugs and Therapy|January 25, 2019
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?Carlos G Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, et al.
Journal of the American College of Cardiology|November 16, 2020
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection FractionCarlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2020
Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone massSe-Min Kim, Charit Taneja, Helena Perez-Pena, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Telemedicine and Telecare|October 30, 2023
Healthcare utilization impacts of an eConsult program for headache at an academic medical centerMargaret H Downes, Rachelle Morgenstern, Georges Naasan, et al.
Cardiovascular Drugs and Therapy|January 25, 2019
Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?Carlos G Santos-Gallego, Alvaro Garcia-Ropero, Donna Mancini, et al.
Journal of the American College of Cardiology|November 16, 2020
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection FractionCarlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 10, 2020
Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone massSe-Min Kim, Charit Taneja, Helena Perez-Pena, et al.
Pageof 3